Glenmark OKed to launch FabiFlu for COVID-19 patients in India

19 June 2020

Glenmark Pharmaceuticals (BSE: 532296) today revealed it has just received manufacturing and marketing approval from India’s drug regulator to launch the oral antiviral drug favipiravir, trade name FabiFlu, for the treatment of mild to moderate COVID-19 patients in India.

This approval has been granted based on evaluation of data and in consultation with the Subject Expert Committee, as part of accelerated approval process, considering the emergency situation and unmet medical need of the COVID-19 outbreak. 12It is for restricted emergency use in India.

Restricted use entails responsible medication use where every patient must have signed informed consent before treatment initiation, says Glenmark, who is also testing a combination of favipiravir and umifenovir, another anti-viral drug, as a potential COVID-19 treatment.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK